Everolimus, Letrozole, and Metformin: New Phase 2 Results in Endometrial Cancer

원문 링크: WordPress 원문

AI-generated conceptual illustration; not study data.

A completed Phase 2 study of everolimus, letrozole, and metformin for advanced or recurrent endometrial carcinoma has a newly posted results record. The trial enrolled 62 people. Among the 54 participants described as evaluable for the primary outcome, the registry records 27 clinical-benefit results.

That is the news. It is not, by itself, a verdict on where this three-drug regimen belongs in treatment. The study had one treatment group and no concurrently assigned comparator, so the record can describe what happened in this cohort without showing that the regimen performed better than another option.

How to read this result: The primary registry record is ClinicalTrials.gov NCT01797523. It reports a defined cohort, a stated analysis population, and a newly available results table—not regulatory approval or comparative effectiveness.

What was newly posted

The newly available entry comes from a single-arm, interventional Phase 2 study led by MD Anderson Cancer Center. It enrolled adults with advanced or recurrent endometrial carcinoma and lists everolimus, letrozole, and metformin as the study combination.

Single-arm means that everyone in the reported group received the same regimen. There was no randomized control group receiving another treatment at the same time. That design is useful for documenting a signal and planning the next question, but it cannot settle a treatment ranking.

The registry now makes the planned endpoint, participant flow, and reported outcomes available in one official place. A results posting matters because it lets readers inspect the numbers and their definitions directly, even before a full peer-reviewed report is available.

What the 27 result means

The primary outcome was clinical benefit under RECIST v1.1. In this record, that outcome combines complete response, partial response, and stable disease. The results table lists 27 clinical-benefit results among 54 evaluable participants, alongside 15 partial-response entries and 12 stable-disease entries.

The denominator matters as much as the numerator. The trial enrolled 62 participants, but the primary-outcome table explicitly identifies 54 evaluable participants. The participant-flow table also reports 54 people as having completed the overall study and eight as not completing it; those related labels should not be silently treated as the same analytic definition.

For that reason, the narrow reading is the most useful one: the registry reports 27 clinical-benefit results in its defined evaluable group. It does not provide a randomized comparison that would show how often the same outcome would have occurred with another treatment.

AI-generated conceptual illustration; not study data.

What 5.7 months of progression-free survival can—and cannot—say

The registry also lists median progression-free survival as 5.7 months for the 54 evaluable participants, with a displayed 95% confidence interval of 3 to 8.2 months. Progression-free survival is the time to recorded disease progression or death in the study analysis.

This number describes the course observed in this particular group. It does not answer the question most people naturally ask next: whether the combination extends progression-free survival more than another available treatment. A concurrent comparator would be needed to address that question directly.

Prior therapy, disease features, assessment timing, supportive care, and chance can all influence an observed outcome. Without a comparison group, the registry cannot separate those influences from the contribution of the drug combination itself.

Why the safety numbers need their own denominator

The efficacy and safety results do not use one universal participant count. Clinical benefit is reported for 54 evaluable participants. The toxicity outcome instead describes 59 participants who received at least one treatment dose and had a follow-up evaluation for side effects.

The safety table lists categories including anemia, hypertriglyceridemia, hyperglycemia, hyponatremia, fatigue, and thrombocytopenia. The registry also has a separate serious-adverse-event table. These entries are a reason to read safety carefully, not a reason to compress safety into a quick positive or negative headline.

Keeping the two populations separate prevents an easy mistake: using an efficacy result and a safety result as though they were calculated from exactly the same group. They were not.

AI-generated conceptual illustration; not study data.

What would make the picture clearer

A full peer-reviewed report could add follow-up detail, reasons for discontinuation, dose changes, missing-data handling, and how adverse events were graded and managed. It could also clarify whether the endpoint definitions and analysis population remain consistent across all reporting.

The more decisive next step would be comparative evidence: a study that evaluates the combination against an appropriate alternative in a clearly defined population. Until then, this registry result is best treated as a dated record of outcomes from one cohort, not a treatment recommendation.

For patients and families, the practical point is not to turn a registry number into a personal prediction. Questions about treatment belong with an oncology team that can consider pathology, prior therapy, overall health, local availability, and current guidelines.

Evidence boundary. This article describes a completed single-arm registry result. It does not establish comparative benefit, causation, individual response, regulatory approval, or a treatment recommendation.

Primary source: ClinicalTrials.gov NCT01797523 official results record · 한국어

Image note: The images are conceptual AI-generated illustrations, not study data. This article is not medical advice.